NEW YORK — Bausch + Lomb presented a bold vision for its future on Thursday during an investor day event at the New York Stock Exchange. Presenting in front of analysts, investors, company leadership, media, and other stakeholders, B+L unveiled a strategic roadmap designed to accelerate growth, expand margins, and reshape the company’s role in advancing ocular science.

Brent Saunders, chairman and CEO of B+L, emphasized the company's reinvention since he resumed his leadership position in 2023—with a focus on simplifying operations, strengthening culture, and embracing cutting-edge technologies such as artificial intelligence. These changes aim to position the company for sustained, profitable growth across all segments of the eye health market, he said. 

“Bausch + Lomb today is a fundamentally different company than it was just a few years ago,” Mr. Saunders said. “We’ve reignited a sense of ownership and ambition across the organization to better serve patients, customers and consumers and deliver sustainable, profitable growth.”

The transformation has included operational streamlining, a sharpened focus on execution, and renewed investment in innovation, all of which are designed to drive value for both patients and shareholders. Bausch + Lomb leadership outlined a 3-year strategy aimed at delivering above-market revenue growth and significant margin expansion through 2028.

Key Financial Targets (2026–2028)

  • 5–7% constant currency revenue CAGR driven by core business momentum and new product launches

  • ~23% adjusted EBITDA margin by 2028

  • Double-digit adjusted EPS growth (ex. Acq. IPR&D)

  • 50% adjusted cash flow from operations to adjusted EBITDA conversion by 2028

  • Net leverage of ~3.5x by year-end 2028

The company also reaffirmed its 2025 guidance.

A major focus of the event was Bausch + Lomb’s R&D pipeline, now projected to deliver approximately $7 billion in total peak sales over time, with launches staggered through the next decade. Leadership highlighted advances across consumer, pharmaceutical, surgical, and contact lens categories.

“One of the important messages we delivered here at Investor Day was unveiling the depth of our pipeline across all of our businesses," Mr. Saunder told Eyewire+. "And this is something I started working on since rejoining the company 3 years ago, so it was really rewarding to be able to unveil that today. And probably the most important characteristic of our pipeline is so many of our new products are first-in-class.”

Pipeline Highlights by Business Unit

Consumer

  • PreserVision AREDS3: New formulation adding a proprietary vitamin B complex for AMD support (launch expected 1H 2026)

  • Lumify reformulation: Brimonidine + hyaluronic acid for a more luxurious, fast-acting redness reliever (1H 2027)

  • Blink Triple Care preservative-free lipid-based formula and advanced bottle technology (1H 2026)

Pharmaceuticals

  • Dual-action dry eye therapy combining Miebo and Xiidra to target both evaporative and inflammatory causes (~2029)

  • First neurosensory-targeted therapy for ocular surface pain—the top reason for eye care visits (~2030)

  • Glaucoma therapy designed to treat vision loss in addition to lowering intraocular pressure (~2031)

  • Early-stage collaborations targeting intermediate AMD and geographic atrophy (2030+)

Surgical

  • enVista Beyond IOL with pure refractive optics for extended depth of focus and fewer dysphotopsias (2027)

  • Elios, an implant-free minimally invasive glaucoma surgery already approved in Europe (U.S. launch 2H 2026)

  • SeeNova phaco/vitreoretinal platform for enhanced fluidics and multifunction handpieces (2028)

  • SeeLyra next-generation femtosecond laser with live OCT guidance (2H 2026)

Contact Lens

  • Bioactive hyaluronic acid hydrogel lens—a potential industry-first material breakthrough in 25+ years (2028)

  • Cost-competitive daily disposable silicone hydrogel lens for price-conscious patients (2029)

  • Premium silicone hydrogel frequent replacement lens for elevated comfort (2029)

  • Myopia control lens for children and adolescents to address a rapidly growing global need (2029)